L-2-oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases

Melanoma Research

Volumn 12, Issue 1, 2002, Pages 17-26

  Bilbao, P ^a,b   Del Olmo, M ^a   Alonso Varona, A ^a   Castro, B ^a   Bilbao, J ^a   Palomares, T ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

B16 melanoma; Biochemotherapy; Cyclophosphamide; Interleukin 2; L 2 oxothiazolidine 4 carboxylate

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; CYCLOPHOSPHAMIDE; GLUTATHIONE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL PROTECTION; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; IMMUNOTHERAPY; LIVER METASTASIS; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; FEMALE; GLUTATHIONE; INTERLEUKIN-2; LIVER; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PYRROLIDONECARBOXYLIC ACID; THIAZOLES; THIAZOLIDINES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036189671     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200202000-00004     Document Type: Article

References (47)

1. Systemic treatment of metastatic melanoma with chemotherapy
2. New approaches to the systemic treatment of melanoma
3. Interleukin-2 plus chemotherapy for patients with metastatic melanoma
4. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
5. Sequential chemo-immunotherapy for metastatic melanoma
6. The feasibility of repetitive courses of high-dose continuous intravenous infusion interleukin-2 and subcutaneous alpha-interferon with polychemotherapy in advanced malignant melanoma
7. Cytotoxic drug resistance: Molecular basis and clinical significance
8. B16F10 murine melanoma cells express interleukin-2 and a functional interleukin-2 receptor
9. Interleukin 2 receptor expression and interleukin 2 localization in human solid tumour cells in situ and in vitro: Evidence for a direct role in the regulation of tumour cell proliferation
10. Expression of IL-2 in human melanoma cells
11. The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma
12. Cyclosporine A upmodulates the α-subunit of the interleukin-2 receptor and the metastatic ability of murine B16F10 melanoma cells
13. Interleukin-2 increases intracellular glutathione levels and reverses the growth-inhibiting effects of cyclophosphamide on B16 melanoma cells
14. Glutathione
15. Glutathione deficiency produced by inhibition of its synthesis, and its reversal: Applications in research and therapy
16. DNA damage in cyclophosphamide resistant tumor cells: The role of glutathione
17. Role of thiol compounds in mammalian melanin pigmentation: Part I. Reduced and oxidized glutathione
18. Effect of L-dopa methylester and glutathione depletion on murine B16 melanoma growth in vitro
19. Differential sensitivities of murine melanocytes and melanoma cells to buthionine sulfoximine and anti-cancer drugs
20. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulphoximine on chemosensitization and tumour growth of B16 melanoma
21. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan
22. Development of a novel glutathione repleting agent, L-2-oxothiazolidine-4-carboxylic acid (Procysteine)
23. Effects of L-2-oxothiazolidine-4-carboxylate on the cytotoxic activity and toxicity of cyclophosphamide in mice bearing B16F10 melanoma liver metastases
24. Sensitization effect of L-2-oxothiazolidine-4-carboxylate on tumor cells to melphalan and the role of 5-oxo- L-prolinase in glutathione modulation in tumor cells
25. Characterization of 5-oxo-L-prolinase in normal and tumor tissues of humans and rats: A potential new target for biochemical modulation of glutathione
26. Glutathione regulates interleukin-2 activity on cytotoxic T-cells
27. Comparative study of intracellular glutathione content in rat lymphocyte cultures treated with 2-mercaptoethanol and interleukin-2
28. Noncorrelation between implantation and growth of tumour cells for their final metastatic efficiency
29. New colorimetric cytotoxicity assay for anti-cancer-drug screening
30. UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia
31. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
32. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo
33. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells
34. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer
35. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: Clinical and biochemical results
36. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine
37. Reversal of multiple-site tumour cell-induced immunosuppression by specific cytokines and pharmacological agents
38. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells
39. Regulation by glutathione of the activation and differentiation of IL-4-dependent activated killer cells
40. Differential effects of ifosfamide on the capacity of cytotoxic T lymphocytes and natural killer cells to lyse their target cells correlate with intracellular glutathione levels
41. A comparison of the effects of ifosfamide vs mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets
42. Cell cycle progression of glutathione-depleted human peripheral blood mononuclear cells in inhibited at S phase
43. IL-2 induced cellular events
44. Irreversible inactivation of protein kinase C by glutathione
45. Possible availability of N-acetylcysteine as an adjunct to cytokine therapy for hepatocellular carcinoma
46. Functions of glutathione and glutathione disulfide in immunology and immunopathology
47. Protection by L-2-oxothiazolidine-4-carboxylic acid of hydrogen peroxide-induced CD3ζ and CD16 ζ chain down-regulation in human peripheral blood lymphocytes and lymphokine-activated killer cells